BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Quarterly EPS Estimate At $-0.19


The EPS estimate of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for quarter completed 2017-03-31 is $-0.19.

The EPS predictions registered a week and month ago were $-0.19 and $-0.19 correspondingly. EPS estimates registered in preceding 60 and 90 days were $-0.19 and $-0.19 correspondingly. The variance in EPS predictions over previous week is 0%.

The count of EPS reviews negative and up over previous week was 0 and 0, correspondingly. The affirmative EPS review in the prior 30 and 60 days were 1, and 1, however, for 90 and 120 days were 1 and 0.

The EPS negative assessments in the last 30 and 60 days was 0, and 0, though in, 90 and 120 days was 0 and 0.

The positive and negative review of per-share earnings in the earlier 18 days were 0 and 0 correspondingly.

Earnings Surprises

The mean EPS approximation previous to the financial report statement for the period closed 3 is $-0.19 calculated as per 7 EPS predictions. The financial account performance was released on 2016-11-07 and EPS was $-0.16. The surprise count was $0.07 per share and seen in fraction, it was 30.43%. The standard deviation of given EPS prior to release is $0.06.

Quarterly Sales Estimates

The mean of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) annual sales estimates is $4.727 and the median of sales predictions is $4.891. The estimate is computed by 5 analysts for the fiscal 2016.

The highest yearly prediction is $6.484 and the lowest estimate is $2.72. Annual sales estimates demonstrate standard deviation of $1.408.

The number of analysts reviewing the equity and folks who have abridged and upped sales prediction in the prior week are 5 and 5 correspondingly. The modification in the mean prediction is 0%.

The analysts casing the security and those who have lowered and upped prediction for sales in the prior month are 5 and 5 correspondingly. From last month, the alteration in the mean estimate is -5.004%.

The analysts count after the stock and those who have lowered and upped estimate for sales in the former quarter are 5 and 5 respectively. From earlier quarter, the alteration in the mean estimate is -9.444%.

1 Chart Pattern Every Investor Should Know

This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...

Click Here to See This Now.

(Visited 11 times, 1 visits today)